Abstract
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse – effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant Englishlanguage literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.
Keywords: Capecitabine, esophageal cancer, gastric cancer, gastroesophageal cancer, colorectal cancer, hepatic cancer, biliary tract cancer, gallbladder cancer, pancreatic cancer
Reviews on Recent Clinical Trials
Title: The Role of Capecitabine in the Management of Tumors of the Digestive System
Volume: 4 Issue: 1
Author(s): Constantine Gennatas, Vasiliki Michalaki and Spyridon Gennatas
Affiliation:
Keywords: Capecitabine, esophageal cancer, gastric cancer, gastroesophageal cancer, colorectal cancer, hepatic cancer, biliary tract cancer, gallbladder cancer, pancreatic cancer
Abstract: Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse – effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant Englishlanguage literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.
Export Options
About this article
Cite this article as:
Gennatas Constantine, Michalaki Vasiliki and Gennatas Spyridon, The Role of Capecitabine in the Management of Tumors of the Digestive System, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047576
DOI https://dx.doi.org/10.2174/157488709787047576 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Sigma-2 Receptor as a Potential Drug Target
Current Medicinal Chemistry Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Chemo-Radiation Association in Head and Neck Squamous Cell Carcinoma: Evidences and Criticisms
Current Drug Therapy CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An <i>In Silico</i> Study
Medicinal Chemistry Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets An Insight of Molecular Mechanisms and Patents of Biomarkers of Human Papilloma Virus Associated with Cancer : A Review
Recent Patents on Biomarkers Skin as a Novel Route for Allergen-specific Immunotherapy
Current Pharmaceutical Design High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer
MicroRNA